Published in Arthritis Rheum on December 01, 2010
Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis (2016) 1.55
Comparative study of clinical grade human tolerogenic dendritic cells. J Transl Med (2011) 1.12
Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? Clin Exp Immunol (2013) 1.09
Therapeutic potential of semi-mature dendritic cells for tolerance induction. Front Immunol (2012) 1.01
siRNA-based therapeutic approaches for rheumatic diseases. Nat Rev Rheumatol (2012) 0.90
Protection of islet grafts through transforming growth factor-β-induced tolerogenic dendritic cells. Diabetes (2013) 0.89
Dendritic cells and the promise of antigen-specific therapy in rheumatoid arthritis. Arthritis Res Ther (2013) 0.88
Tolerance in organ transplantation: from conventional immunosuppression to extracellular vesicles. Front Immunol (2014) 0.88
Regulatory dendritic cell therapy: from rodents to clinical application. Immunol Lett (2013) 0.87
The dark side of dendritic cells: development and exploitation of tolerogenic activity that favor tumor outgrowth and immune escape. Front Immunol (2013) 0.83
Dendritic cells as gatekeepers of tolerance. Semin Immunopathol (2016) 0.83
Expression of ESE-3 isoforms in immunogenic and tolerogenic human monocyte-derived dendritic cells. PLoS One (2012) 0.82
Tolerogenic dendritic cells and rheumatoid arthritis: current status and perspectives. Rheumatol Int (2011) 0.81
A mouse model of adoptive immunotherapeutic targeting of autoimmune arthritis using allo-tolerogenic dendritic cells. PLoS One (2013) 0.80
Generation of Tolerogenic Dendritic Cells and Their Therapeutic Applications. Immune Netw (2016) 0.80
In vitro suppression of immune responses using monocyte-derived tolerogenic dendritic cells from patients with primary Sjögren's syndrome. Arthritis Res Ther (2013) 0.79
MERTK as negative regulator of human T cell activation. J Leukoc Biol (2015) 0.79
Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance. J Immunol Res (2016) 0.79
Therapeutic effects of tolerogenic dendritic cells. Nat Rev Rheumatol (2010) 0.79
Gene Expression Profiling of Human Monocyte-derived Dendritic Cells - Searching for Molecular Regulators of Tolerogenicity. Front Immunol (2015) 0.78
1,25-Dihydroxyvitamin D3-Conditioned CD11c+ Dendritic Cells are Effective Initiators of CNS Autoimmune Disease. Front Immunol (2015) 0.77
NF-κB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment. Oncotarget (2015) 0.77
Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4(+) T cells partly via transforming growth factor-β1. Clin Exp Immunol (2016) 0.77
Dendritic Cell-based Immunotherapy for Rheumatoid Arthritis: from Bench to Bedside. Immune Netw (2016) 0.77
Tolerogenic dendritic cells that inhibit autoimmune arthritis can be induced by a combination of carvacrol and thermal stress. PLoS One (2012) 0.77
Therapeutic Potential of Hyporesponsive CD4(+) T Cells in Autoimmunity. Front Immunol (2015) 0.76
Dexamethasone and Monophosphoryl Lipid A-Modulated Dendritic Cells Promote Antigen-Specific Tolerogenic Properties on Naive and Memory CD4(+) T Cells. Front Immunol (2016) 0.76
Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential. Front Immunol (2017) 0.75
Immunomodulatory Effects of 1,25-Dihydroxyvitamin D3 on Dendritic Cells Promote Induction of T Cell Hyporesponsiveness to Myelin-Derived Antigens. J Immunol Res (2016) 0.75
Immune-regulatory mechanisms in systemic autoimmune and rheumatic diseases. Clin Dev Immunol (2011) 0.75
LPS-primed Heterotolerant Dendritic Cells suppress Experimental Autoimmune Uveoretintitis by multiple mechanisms. Immunology (2016) 0.75
The thymus and rheumatology: should we care? Curr Opin Rheumatol (2016) 0.75
The choice of adjuvant determines the cytokine profile of T cells in proteoglycan-induced arthritis but does not influence disease severity. Immunology (2013) 0.75
Treatment with Dexamethasone and Monophosphoryl Lipid A Removes Disease-Associated Transcriptional Signatures in Monocyte-Derived Dendritic Cells from Rheumatoid Arthritis Patients and Confers Tolerogenic Features. Front Immunol (2016) 0.75
Renal Allograft Survival in Nonhuman Primates Infused With Donor Antigen-Pulsed Autologous Regulatory Dendritic Cells. Am J Transplant (2016) 0.75
Parasitic infection as a potential therapeutic tool against rheumatoid arthritis. Exp Ther Med (2016) 0.75
Early-Life Nutritional Factors and Mucosal Immunity in the Development of Autoimmune Diabetes. Front Immunol (2017) 0.75
Autologous tolerogenic dendritic cells derived from monocytes of systemic lupus erythematosus patients and healthy donors show a stable and immunosuppressive phenotype. Immunology (2017) 0.75
Tolerogenic dendritic cells induced by BD750 ameliorate proinflammatory T cell responses and experimental autoimmune encephalitis in mice. Mol Med (2017) 0.75
Emerging immunotherapies for rheumatoid arthritis. Hum Vaccin Immunother (2014) 0.75
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity (2013) 2.69
Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J Immunol (2007) 2.19
Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis. Arthritis Care Res (Hoboken) (2014) 2.11
Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum (2010) 2.08
Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol (2003) 2.05
The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis (2012) 2.03
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med (2013) 1.67
Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. Ann Rheum Dis (2009) 1.62
Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. Blood (2002) 1.57
Integrated safety in tocilizumab clinical trials. Arthritis Res Ther (2011) 1.55
Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet (2013) 1.54
Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov (2007) 1.45
Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum (2011) 1.44
Differential regulation of naïve and memory CD4+ T cells by alternatively activated dendritic cells. J Leukoc Biol (2008) 1.40
Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis (2013) 1.37
Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis (2010) 1.29
Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. Arthritis Rheum (2010) 1.29
Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol (2011) 1.27
Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest (2014) 1.25
Development of dendritic cell-based immunotherapy for autoimmunity. Int Rev Immunol (2010) 1.24
LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol (2008) 1.23
Cell-type and donor-specific transcriptional responses to interferon-alpha. Use of customized gene arrays. J Biol Chem (2002) 1.20
Anti-TNF therapy. Best Pract Res Clin Rheumatol (2011) 1.18
Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum (2012) 1.17
Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet (2008) 1.16
Low-strength T-cell activation promotes Th17 responses. Blood (2010) 1.15
Sustained IL-12 signaling is required for Th1 development. J Immunol (2004) 1.15
Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Res Ther (2006) 1.13
A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation. J Immunol (2005) 1.12
FcγRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy. PLoS One (2012) 1.07
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis (2010) 1.06
Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Arthritis Res Ther (2004) 1.04
Apoptotic cells induce dendritic cell-mediated suppression via interferon-gamma-induced IDO. Immunology (2007) 1.04
Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci (2004) 1.03
Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes. J Immunol (2010) 1.02
A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. Ann Rheum Dis (2012) 1.02
Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. Arthritis Rheum (2008) 1.01
Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Allergy Clin Immunol (2010) 1.01
Sequential proteolytic processing of the capsular Caf1 antigen of Yersinia pestis for major histocompatibility complex class II-restricted presentation to T lymphocytes. J Biol Chem (2006) 1.01
Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up. Arthritis Res Ther (2012) 1.00
Inhibition of macropinocytosis blocks antigen presentation of type II collagen in vitro and in vivo in HLA-DR1 transgenic mice. Arthritis Res Ther (2006) 0.99
Efficacy of a single ultrasound-guided injection for the treatment of hip osteoarthritis. Ann Rheum Dis (2010) 0.99
Regulatory T cells and autoimmunity. Curr Opin Hematol (2009) 0.98
Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract Res Clin Rheumatol (2009) 0.97
Differential processing of CD4 T-cell epitopes from the protective antigen of Bacillus anthracis. J Biol Chem (2003) 0.96
Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis (2010) 0.96
Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol (2004) 0.95
Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. Hum Mutat (2012) 0.94
Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis (2010) 0.93
NK cells developing in vitro from fetal mouse progenitors express at least one member of the Ly49 family that is acquired in a time-dependent and stochastic manner independently of CD94 and NKG2. Eur J Immunol (2002) 0.93
Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B. Arthritis Res Ther (2006) 0.91
Effects of alcohol on risk-taking during simulated driving. Hum Psychopharmacol (2002) 0.91
Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer. Hum Mol Genet (2002) 0.91
Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet Genomics (2009) 0.91
High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: short-term efficacy correlates with reduction of macroscopic and histologic synovitis. Arthritis Rheum (2002) 0.90
The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model. Arthritis Rheum (2006) 0.90
Mechanisms of major histocompatibility complex class II-restricted processing and presentation of the V antigen of Yersinia pestis. Immunology (2006) 0.90
Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models? Ann Rheum Dis (2011) 0.90
Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther (2013) 0.90
Predicting persistent inflammatory arthritis amongst early arthritis clinic patients in the UK: is musculoskeletal ultrasound required? Arthritis Res Ther (2013) 0.90
TGF-beta1 and IFN-gamma cross-regulate antigen presentation to CD4 T cells by macrophages. J Leukoc Biol (2002) 0.89
Profound invariant natural killer T-cell deficiency in inflammatory arthritis. Ann Rheum Dis (2010) 0.88
Treg cells in rheumatoid arthritis: an update. Curr Rheumatol Rep (2013) 0.87
Alemtuzumab (Campath-1H) for treatment of refractory polymyositis. J Rheumatol (2008) 0.87
Processing of viable Salmonella typhimurium for presentation of a CD4 T cell epitope from the Salmonella invasion protein C (SipC). Eur J Immunol (2002) 0.87
Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. Ann Rheum Dis (2009) 0.87
CD4+CD25+ T-regulatory cells are decreased in patients with autoimmune polyendocrinopathy candidiasis ectodermal dystrophy. J Allergy Clin Immunol (2005) 0.86
Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Arthritis Res Ther (2012) 0.86
Invariant natural killer T (iNKT) cell deficiency in chronic mucocutaneous candidiasis--a consequence or a cause? Immunol Lett (2010) 0.86
Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis. Rheumatology (Oxford) (2011) 0.85
Localization of peptide/MHC class II complexes in macrophages following antigen processing of viable Streptococcus pyogenes. Eur J Immunol (2003) 0.85
Serotyping for an extended anti-citrullinated peptide autoantibody panel does not add value to CCP2 testing for diagnosing RA in an early undifferentiated arthritis cohort. Ann Rheum Dis (2011) 0.85
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Res Ther (2014) 0.85
Repertoire of HLA-DR1-restricted CD4 T-cell responses to capsular Caf1 antigen of Yersinia pestis in human leukocyte antigen transgenic mice. Infect Immun (2010) 0.84
Biologic therapies in non-rheumatic diseases: lessons for rheumatologists? Nat Rev Rheumatol (2011) 0.84
Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming. Transplantation (2009) 0.84
Attenuated Salmonella typhimurium htrA mutants cause fatal infections in mice deficient in NADPH oxidase and destroy NADPH oxidase-deficient macrophage monolayers. Vaccine (2004) 0.84
Immunogenicity of a Yersinia pestis vaccine antigen monomerized by circular permutation. Infect Immun (2006) 0.83
The route of bacterial uptake by macrophages influences the repertoire of epitopes presented to CD4 T cells. Eur J Immunol (2002) 0.83
Presentation of the candidate rheumatoid arthritis autoantigen aggrecan by antigen-specific B cells induces enhanced CD4(+) T helper type 1 subset differentiation. Immunology (2012) 0.82
Impact of psoralen/UVA-treatment on survival, activation, and immunostimulatory capacity of monocyte-derived dendritic cells. Transplantation (2008) 0.82